Invasive Breast Cancer Version 1.2016 Clinical Practice Guidelines in Oncology
Invasive Breast Cancer Version 1.2016 Clinical Practice Guidelines in Oncology
复制标题
DOI：
10.6004/jnccn.2016.0037
复制
发表时间：
2016-03-01
影响因子：
13.4
通讯作者：
Kumar, Rashmi
中科院分区：
文献类型：
--
作者：
Gradishar, William J.;Anderson, Benjamin O.;Kumar, Rashmi
乳腺癌是美国女性最常见的恶性肿瘤，是仅次于肺癌的癌症死亡原因。乳腺癌的总体管理包括用手术、放射疗法或两者治疗局部疾病，以及用细胞毒性化疗、内分泌疗法、生物疗法或这些疗法的组合治疗全身性疾病。本文概述了NCCN针对局部（仅限于身体的一个区域）乳腺癌的指南，并讨论了临床I，II和IIIA期（T3N1M0）肿瘤的管理。对于NCCN关于临床阶段I，II和IIIA（T3N1M0）局部区域管理后的全身辅助治疗指南以及其他临床阶段乳腺癌的管理，请参见NCCN.org上这些指南的完整版本。
Breast cancer is the most common malignancy in women in the United States and is second only to lung cancer as a cause of cancer death. The overall management of breast cancer includes the treatment of local disease with surgery, radiation therapy, or both, and the treatment of systemic disease with cytotoxic chemotherapy, endocrine therapy, biologic therapy, or combinations of these. This article outlines the NCCN Guidelines specific to breast cancer that is locoregional (restricted to one region of the body), and discusses the management of clinical stage I, II, and IIIA (T3N1M0) tumors. For NCCN Guidelines on systemic adjuvant therapy after locoregional management of clinical stage I, II and IIIA (T3N1M0) and for management for other clinical stages of breast cancer, see the complete version of these guidelines at NCCN.org.